Latest news with #INSIGHT
Time of India
6 days ago
- Entertainment
- Time of India
Omos to return to WWE programming soon? Nigerian star has this to say
It's been a while since fans last saw Omos in a WWE ring. Known for his towering presence and powerhouse style, the Nigerian Giant has quietly stepped out of the weekly spotlight in recent months. His last WWE appearance came in April 2024, when he featured in the Andre the Giant Memorial Battle Royal on SmackDown. Since then, Omos has been off the radar, sparking questions, speculation, and plenty of curiosity among fans and wrestling insiders. Now, in a new interview on INSIGHT with Chris Van Vliet, Omos has spoken openly about his situation. He's not injured. He hasn't been forgotten. He's waiting for the right time to make an impact again. The 7-foot-3 WWE star also opened up about his time in Japan, why he sees himself as a special attraction, and how WWE legend The Undertaker continues to guide him through key moments of his career. His comments give fans a rare look behind the curtain and make it clear that Omos is far from finished. 'I'm just waiting': Omos on being absent from WWE programming Omos must have the best laugh ever WWE fans would love to see him back Omos made it clear that his absence is part of a bigger picture. He called himself a 'special attraction' in WWE, someone who appears for big moments, not every week. 'I don't know. I'm just waiting,' he told YouTuber Chris Van Vliet. 'I'm kind of in a scenario where I'm like a special attraction. Whenever that time comes, I'm ready.' That kind of role isn't new in wrestling, but for someone still early in their career, it's unique, and it speaks to how WWE views his presence. During his break from WWE programming, Omos spent time competing in Japan's Pro Wrestling NOAH. He teamed up with Jack Morris to win the GHC Tag Team titles at the beginning of 2025, a huge moment in his career. Although their reign was short-lived, the trip meant a lot to Omos. He shared how excited he was just to be there, especially after hearing Great Muta name-drop him in an interview as someone he wanted to see wrestle in Japan. He also credited The Undertaker as a massive influence during this time. Omos explained how 'Taker has become a mentor figure, someone he speaks with often for advice. 'He can't be my dad, sorry Taker, but he's been such a great influence on me,' Omos said. 'I always ask, what would Undertaker do?' Right now, there's no clear date for his return. But Omos made it clear that he's not idle; rather, he's just being patient. Whether it's another showdown with a top name or a surprise return on a major stage, the Nigerian Giant sounds ready. And when the moment comes, he wants to make sure it's unforgettable.
CNA
29-05-2025
- Business
- CNA
Insight 2025/2026 - Trump's 100 Days: Trader Woes in Asia
INSIGHT is a one hour long hard current affairs programme that aims to open the minds of viewers to the political, social and economic realities facing today's societies. Every week, a team of producers will bring forward compelling arguments, impartial analysis and penetrating insights into topical issues of the day. What's on the menu are topics of concerns that have set the region talking as well as changing trends and events which impact Asia and beyond. INSIGHT will get you closer to the heart of the issues with insightful interviews and engaging conversations, bringing to you the real story from behind extraordinary experiences.
Business Upturn
22-05-2025
- Health
- Business Upturn
Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting
LOUISVILLE, Colo., May 22, 2025 (GLOBE NEWSWIRE) — Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced today that new data will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois at 2:30 pm ET on Saturday, May 31st. The presentation titled 'Host immune classifier to predict survival with chemoimmunotherapy in PD-L1 ≥50% metastatic NSCLC' features data from the INSIGHT study (NCT03289780) which enrolled greater than 5,000 patients with non-small cell lung cancer (NSCLC). The data will be presented by Dr. Vamsidhar Velcheti, MD, Director of Thoracic Oncology at NYU Langone's Perlmutter Cancer Center. The VeriStrat test measures a patient's immune response to lung cancer and is reported as either Host Immune Classifier Hot ( VeriStrat Good ) or Host Immune Classifier Cold ( VeriStrat Poor ). The new data strengthens prior findings and demonstrates statistically significant improvement of overall survival (OS) in patients with a VeriStrat Poor result when receiving immunotherapy combined with chemotherapy versus immunotherapy as a single agent. Notably, the two-year survival rate was more than three times higher in patients receiving immunotherapy plus chemotherapy compared to those who received immunotherapy alone. Additionally, patients with a VeriStrat Good result had comparable survival when receiving either treatment regimen. 'Immunotherapy treatments represent one of the most important recent innovations in lung cancer treatment, unfortunately some patients do not respond to these treatments while others may experience adverse reactions,' said Gary Pestano, Ph.D., Chief Development Officer, Biodesix. 'This new data suggests that the VeriStrat test has the potential to help oncologists evaluate the benefits and risks of certain treatments for specific patients. The VeriStrat test may then be an aid in decision-making on whether to escalate or de-escalate treatment and improve patient outcomes.' Preliminary results from a different ongoing study suggest that the VeriStrat test may have similar indications in patients with other types of solid tumors. Data from this study is expected to be published later in 2025. About Biodesix Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung® Nodule Risk Assessment and IQLung™ Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world's leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit Trademarks: Biodesix, Biodesix Logo, Nodify Lung, and IQLung are trademarks or registered trademarks of Biodesix, Inc. Contacts: Media:Natalie St. Denis, Director Corporate Communications, Biodesix [email protected] (720) 925-9285
Yahoo
22-05-2025
- Health
- Yahoo
Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting
New data from the INSIGHT study demonstrates the VeriStrat Host Immune Classifier (HIC)'s ability to predict overall survival in patients with non-small cell lung cancer treated with immunotherapy LOUISVILLE, Colo., May 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced today that new data will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois at 2:30 pm ET on Saturday, May 31st. The presentation titled 'Host immune classifier to predict survival with chemoimmunotherapy in PD-L1 ≥50% metastatic NSCLC' features data from the INSIGHT study (NCT03289780) which enrolled greater than 5,000 patients with non-small cell lung cancer (NSCLC). The data will be presented by Dr. Vamsidhar Velcheti, MD, Director of Thoracic Oncology at NYU Langone's Perlmutter Cancer Center. The VeriStrat test measures a patient's immune response to lung cancer and is reported as either Host Immune Classifier Hot () or Host Immune Classifier Cold (). The new data strengthens prior findings and demonstrates statistically significant improvement of overall survival (OS) in patients with a result when receiving immunotherapy combined with chemotherapy versus immunotherapy as a single agent. Notably, the two-year survival rate was more than three times higher in patients receiving immunotherapy plus chemotherapy compared to those who received immunotherapy alone. Additionally, patients with a result had comparable survival when receiving either treatment regimen. 'Immunotherapy treatments represent one of the most important recent innovations in lung cancer treatment, unfortunately some patients do not respond to these treatments while others may experience adverse reactions,' said Gary Pestano, Ph.D., Chief Development Officer, Biodesix. 'This new data suggests that the VeriStrat test has the potential to help oncologists evaluate the benefits and risks of certain treatments for specific patients. The VeriStrat test may then be an aid in decision-making on whether to escalate or de-escalate treatment and improve patient outcomes.' Preliminary results from a different ongoing study suggest that the VeriStrat test may have similar indications in patients with other types of solid tumors. Data from this study is expected to be published later in 2025. About Biodesix Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung® Nodule Risk Assessment and IQLung™ Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world's leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit Trademarks: Biodesix, Biodesix Logo, Nodify Lung, and IQLung are trademarks or registered trademarks of Biodesix, Inc. Contacts:Media:Natalie St. Denis, Director Corporate Communications, 925-9285 Investors:Chris Brinzey, Partner, ICR 970-2843Sign in to access your portfolio
CNA
22-05-2025
- Entertainment
- CNA
Insight 2025/2026 - Trump's 100 Days : Aid and Asia
INSIGHT is a one hour long hard current affairs programme that aims to open the minds of viewers to the political, social and economic realities facing today's societies. Every week, a team of producers will bring forward compelling arguments, impartial analysis and penetrating insights into topical issues of the day. What's on the menu are topics of concerns that have set the region talking as well as changing trends and events which impact Asia and beyond. INSIGHT will get you closer to the heart of the issues with insightful interviews and engaging conversations, bringing to you the real story from behind extraordinary experiences.
